<DOC>
	<DOCNO>NCT02814630</DOCNO>
	<brief_summary>This single center , non-comparative exploratory study , investigate effect omalizumab 3-month treatment period adult ( ≥18 year ) patient chronic idiopathic urticaria remain symptomatic despite use high dose H1-antihistamines .</brief_summary>
	<brief_title>Three-month , Single-center Study Identify Biomarkers/Response Xolair Therapy Chronic Idiopathic Urticaria</brief_title>
	<detailed_description>This single center , non-comparative exploratory study , investigate effect omalizumab 3-month treatment period adult ( ≥18 year ) patient chronic idiopathic urticaria remain symptomatic despite use high dose H1-antihistamines . After initial screen visit within two week Day 1 baseline visit , patient receive one subcutaneous injection omalizumab dose 300 mg Days 1 , 30 , 60 . Patients return clinical assessment blood draw Day 3 Day 30 ( study conclusion ) . Blood collect screen visit ( Day -14 ) , baseline ( Day 1 , prior omalizumab injection ) , Day 14 , Day 30 ( prior omalizumab injection ) , Day 60 ( prior omalizumab injection ) , Day 90 ( study completion ) microsomal miRNA extraction , basophil isolation , also store -70oC later periostin assay total 275ml blood course study ( 25ml screen 50ml 5 subsequent visit ( i.e. , Days 1 , 14 , 30 , 60 , 90 ) . Plasma exosomal miRNA bioinformatics analysis conduct early ( i.e. , Day 14 ) later ( i.e. , Day 30 , 60 , 90 ) responder group . The 2 wk time point capture early responder 4 , 8 , 12 wk time point capture remain responder group base follow : Two Phase III , global , multicenter , randomize , double-blind , placebo-controlled trial ( Appendix B , CIU Study 1 CIU Study 2 data ) data CIU patient start UAS7 score 25.3 ± 2.0 ( mean ± SEM ) treat Xolair® outside clinical trial ( Metz et al. , 2014 ) , 57 % attain complete response within one week first treatment 29 % within 4 week ( Metz et al. , 2014 ) . To address role/mechanism basophil immunopathogenesis chronic urticaria , basophil mRNA/miRNA array .</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>• least 6 week chronic idiopathic urticaria itch despite current use x4 H1antihistamines ( Kaplan , 2004 ) urticaria activity score ( UAS ) 7day period ( UAS7 ) 16 ( scale range 0 42 , high score indicate great activity minimally important difference [ MID ] 9.5 10.5 ) ( Mathias et al. , 2012 ) weekly itchseverity score ( ISS ) 8 ( scale range 0 21 , high score indicate severe itch MID ≥5 ) 7 day first treatment omalizumab . All female childbearing potential must either abstinent sexual intercourse use adequate contraception must also negative urine pregnancy test . * • clearly define underlying cause chronic urticaria ( e.g. , physical urticaria ) routine administration ( i.e. , daily every day ≥5 consecutive day ) systemic glucocorticoid , hydroxychloroquine , methotrexate , cyclosporine , cyclophosphamide , intravenous immune globulin within previous 30 day use H2antihistamine leukotrienereceptor antagonist within 7 day precede screen visit history cancer know hypersensitivity omalizumab treatment omalizumab within previous year , pregnant nursing females*</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>